

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

Kenneth C. Cundy, et al.

Application No.: 09/972,402

Filed: October 5, 2001

For: Compounds for Sustained Release of
Orally Delivered Drugs

Group Art Unit: 1619

Examiner: Unassigned

TECH CENTER 1600/2900
FEB 01 2002

RECEIVED
#5

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of IDS as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- A certification under 37 C.F.R. § 1.97(e), and the fee of IDS as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,
BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:



Anthony T. Cascio
Registration No. 29,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300
Date: January 29, 2002



Patent Application no. 09/972,402
Attorney's Docket No. 03300-034

FEB 01 2002

TECH CENTER 1600/2900

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of)
Kenneth C. Cundy, et al.) Group Art Unit: 1619
Application No.: 09/972,402) Examiner: Unassigned
Filed: October 5, 2001)
For: Compounds for Sustained Release of)
Orally Delivered Drugs)
)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed:

Articles:

- Gotoh, et al., *J. Pharmacol. Exp. Ther.*, 2000, **292**, pp. 433-439
Iantomasi, et al., *Biochhim. Biophys. Acta*, 1997, **1330**, pp. 274-283
Kouzuki, et al., *J. Pharmacol. Exp. Ther.*, 1999, **288**, pp. 627-634
Salach, et al., *Pharm. Res.*, 1994, **11**, pp. 1429-1434
Suzuki, et al., *Sem. Liver Disease*, 2000, **20**, pp. 251-263
Tokui, et al., *Pharm. Res.*, 1999, **16**, pp. 904-908
Yamazaki, et al., *Drug Metab. Dispos.*, 1997, **15**, pp. 1123-1129

Information Disclosure Statement
Application No. 09/972,402
Attorney's Docket No. 033053-034
Page 2

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Anthony T. Cascio
Registration No. 29,904

Burns, Doane, Swecker & Mathis
P.O. Box 1404
Arlington, VA 22313
Firm Phone: (650) 622-2300

Date: January 29, 2002